98.9%
HPLC Verified
COA
Available
ISO
Certified Lab
Liraglutide
The proven GLP-1 pioneer with years of clinical data
3mg vial | 3mg/vial
About Liraglutide
Liraglutide holds an important place in the history of GLP-1 therapy. As one of the earliest compounds in this class to be extensively studied for weight management, it built the scientific foundation that newer peptides now build upon.
The SCALE trials demonstrated consistent weight loss of 5-8% of body weight, with participants also experiencing improvements in blood pressure, lipid profiles, and markers of pre-diabetes. Its daily dosing schedule allows for precise titration, making it an excellent choice for those who prefer gradual, controlled approaches.
With over 10 years of post-market safety data across millions of users, Liraglutide has one of the most well-characterized safety profiles of any peptide therapy.
Key Benefits
Published Research
SCALE Obesity (N=3,731) showed 8.0% mean weight loss vs 2.6% placebo over 56 weeks. 63.2% of participants lost 5%+ body weight. 10-year cardiovascular safety data available from LEADER trial.
View Full Research LibraryRelated Products
Semaglutide
The gold standard in GLP-1 weight management
Tirzepatide
Dual-action GIP/GLP-1 for maximum results
AOD-9604
Fat-targeting fragment without growth hormone side effects